Icaac PowerPoint PPT Presentations

All Time
Show:
Recommended
Sort by:
ICAAC PowerPoint PPT Presentation
ICAAC - compatible PPT 97 through 2004 ... ANTIRETROVIRAL TREATMENT HIGHLIGHTS An HIV/AIDS Overview from the 44th Annual Interscience Conference on
compatible PPT 97 through 2004 ... ANTIRETROVIRAL TREATMENT HIGHLIGHTS An HIV/AIDS Overview from the 44th Annual Interscience Conference on
| PowerPoint PPT presentation | free to download
TIMs ICAAC 2004 PowerPoint PPT Presentation
TIMs ICAAC 2004 - G Moyle1 , C Sabin2, J Cartledge3, M Johnson2, E Wilkins4, D Churchill5 , ... Median Change in Haemoglobin and Creatinine to Week 48 *P values by Mann-Whitney U test ...
G Moyle1 , C Sabin2, J Cartledge3, M Johnson2, E Wilkins4, D Churchill5 , ... Median Change in Haemoglobin and Creatinine to Week 48 *P values by Mann-Whitney U test ...
| PowerPoint PPT presentation | free to download
TIMs ICAAC 2004 PowerPoint PPT Presentation
TIMs ICAAC 2004 - Changes in Mean Fasting Cholesterol (mmol/l) by baseline Thymidine analog ... Falls in total cholesterol and TGs were predominately seen in individuals on d4T ...
Changes in Mean Fasting Cholesterol (mmol/l) by baseline Thymidine analog ... Falls in total cholesterol and TGs were predominately seen in individuals on d4T ...
| PowerPoint PPT presentation | free to download
TARV Inicial Resumen ICAAC 2004 PowerPoint PPT Presentation
TARV Inicial Resumen ICAAC 2004 - TARV Inicial Resumen ICAAC 2004
TARV Inicial Resumen ICAAC 2004
| PowerPoint PPT presentation | free to view
ICAAC September 28, 2006, San Francisco PowerPoint PPT Presentation
ICAAC September 28, 2006, San Francisco - Safety assessed by PE, ECG and lab measures. Anthim levels measured by ELISA ... No clinically significant ECG changes. AH-101. Pharmacokinetics Data. Anthim ...
Safety assessed by PE, ECG and lab measures. Anthim levels measured by ELISA ... No clinically significant ECG changes. AH-101. Pharmacokinetics Data. Anthim ...
| PowerPoint PPT presentation | free to view
46th ICAAC, San Francisco, 2006 PowerPoint PPT Presentation
46th ICAAC, San Francisco, 2006 - ... (r-hGH) in HIV-1 patients with lipo-dystrophy, but if the effect is maintained is unknown. ... Furthermore concerns about a reduction of subcutaneous fat, ...
... (r-hGH) in HIV-1 patients with lipo-dystrophy, but if the effect is maintained is unknown. ... Furthermore concerns about a reduction of subcutaneous fat, ...
| PowerPoint PPT presentation | free to download
46th ICAAC San Francisco 2630 septembre 2006 PowerPoint PPT Presentation
46th ICAAC San Francisco 2630 septembre 2006 - charge virale 1 000 copies/ml. sensibilit Enfuvirtide valu e par Ph noscript ... atteignent le crit re principal (CV 30 000 copies/ml 2 reprises, ...
charge virale 1 000 copies/ml. sensibilit Enfuvirtide valu e par Ph noscript ... atteignent le crit re principal (CV 30 000 copies/ml 2 reprises, ...
| PowerPoint PPT presentation | free to view
S' aureus vaccine development PowerPoint PPT Presentation
S' aureus vaccine development - food poisoning - no treatment. Ideal vaccine. prevents bacterial adherence ... Staph A heteropolymer (Elusys Therapeutics) ICAAC, 2005. Elusys Therapeutics Inc. ...
food poisoning - no treatment. Ideal vaccine. prevents bacterial adherence ... Staph A heteropolymer (Elusys Therapeutics) ICAAC, 2005. Elusys Therapeutics Inc. ...
| PowerPoint PPT presentation | free to view
Control de la infecci PowerPoint PPT Presentation
Control de la infecci - Control de la infecci n nosocomial: bacterias multirresistentes, una realidad ... Hosp Univ V Macarena. Rodr guez-Ba o et al. ICAAC 2006 ...
Control de la infecci n nosocomial: bacterias multirresistentes, una realidad ... Hosp Univ V Macarena. Rodr guez-Ba o et al. ICAAC 2006 ...
| PowerPoint PPT presentation | free to view
PostExposure Prophylaxis an evidencebased review PowerPoint PPT Presentation
PostExposure Prophylaxis an evidencebased review - 1. Garcia et al. ICAAC, December 2001, Abstract 1325. Case 3 continued ... 2. Kahn JO, Walker BD. N Engl J Med. 1998;339:33-39. ...
1. Garcia et al. ICAAC, December 2001, Abstract 1325. Case 3 continued ... 2. Kahn JO, Walker BD. N Engl J Med. 1998;339:33-39. ...
| PowerPoint PPT presentation | free to view
Eficacia y seguridad de PREZISTA/ritonavir 800/100mg una vez al d PowerPoint PPT Presentation
Eficacia y seguridad de PREZISTA/ritonavir 800/100mg una vez al d - Title: ICAAC/IDSA 2008 PREZISTA SRL Author: Yaswant Dayaram Last modified by: annkhalsa Created Date: 4/2/2008 2:41:04 PM Document presentation format
Title: ICAAC/IDSA 2008 PREZISTA SRL Author: Yaswant Dayaram Last modified by: annkhalsa Created Date: 4/2/2008 2:41:04 PM Document presentation format
| PowerPoint PPT presentation | free to view
Syncope PowerPoint PPT Presentation
Syncope - M.D., M.Sc.(Canada), FIMSA, Senior Consultant Physician & Cardio-Metabolic Specialist Purpose of : To discuss the unique mechanism of action of daptomycin.
M.D., M.Sc.(Canada), FIMSA, Senior Consultant Physician & Cardio-Metabolic Specialist Purpose of : To discuss the unique mechanism of action of daptomycin.
| PowerPoint PPT presentation | free to download
Reemplazo por r PowerPoint PPT Presentation
Reemplazo por r - Reemplazo por r gimen conteniendo ATV Estudio ARIES Estudio INDUMA Estudio ASSURE Estudio ASSURE: reemplazo de ATV/r + TDF/FTC por ATV + ABC/3TC Dise o Punto final ...
Reemplazo por r gimen conteniendo ATV Estudio ARIES Estudio INDUMA Estudio ASSURE Estudio ASSURE: reemplazo de ATV/r + TDF/FTC por ATV + ABC/3TC Dise o Punto final ...
| PowerPoint PPT presentation | free to download
Actualit PowerPoint PPT Presentation
Actualit - Groupe KPC : Klebsiella pneumoniae carbap n mase ; haut niveau de r sistance aux C3G ; r sistance crois e imip n me (IMP) et m rop n me (MRP). ...
Groupe KPC : Klebsiella pneumoniae carbap n mase ; haut niveau de r sistance aux C3G ; r sistance crois e imip n me (IMP) et m rop n me (MRP). ...
| PowerPoint PPT presentation | free to download
Update on Atazanavir and the Early Access Program PowerPoint PPT Presentation
Update on Atazanavir and the Early Access Program - The other studies are currently ongoing. Atazanavir Profile Azapeptide inhibitor of HIV protease Dosed 400 mg QD with food (2 capsules) ...
The other studies are currently ongoing. Atazanavir Profile Azapeptide inhibitor of HIV protease Dosed 400 mg QD with food (2 capsules) ...
| PowerPoint PPT presentation | free to download
PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection PowerPoint PPT Presentation
PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection - PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection Charles Flexner, MD Johns Hopkins University
PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection Charles Flexner, MD Johns Hopkins University
| PowerPoint PPT presentation | free to download
TRATAMIENTO DE PAT PowerPoint PPT Presentation
TRATAMIENTO DE PAT - TRATAMIENTO DE PAT GENOS MULTIRRESISTENTES Es posible la monoterapia en el tratamiento de la infecci n por Pseudomonas? Monoterapia con nuevos antibi ticos en ...
TRATAMIENTO DE PAT GENOS MULTIRRESISTENTES Es posible la monoterapia en el tratamiento de la infecci n por Pseudomonas? Monoterapia con nuevos antibi ticos en ...
| PowerPoint PPT presentation | free to download
Infecciones producidas por bacterias grampositivas: Neumona, bacteriemia, endocarditis, osteomieliti PowerPoint PPT Presentation
Infecciones producidas por bacterias grampositivas: Neumona, bacteriemia, endocarditis, osteomieliti - Los aspectos cl nicos y evolutivos de la neumon a seg n el pat geno causante y ... Infective endocarditis in hemodialysis patients ...
Los aspectos cl nicos y evolutivos de la neumon a seg n el pat geno causante y ... Infective endocarditis in hemodialysis patients ...
| PowerPoint PPT presentation | free to view
Update on Atazanavir and the Early Access Program PowerPoint PPT Presentation
Update on Atazanavir and the Early Access Program - Dosed 400 mg QD with food (2 capsules) Favorable potency and resistance profile ... Superior lipid profile to NFV or RTV/SQV. Safety, efficacy, tolerability ...
Dosed 400 mg QD with food (2 capsules) Favorable potency and resistance profile ... Superior lipid profile to NFV or RTV/SQV. Safety, efficacy, tolerability ...
| PowerPoint PPT presentation | free to view
Emerging Therapies The Candins PowerPoint PPT Presentation
Emerging Therapies The Candins - Lilly Pharmaceuticals. Merck Research Laboratories. Ortho-Biotech. Pfizer, Inc. ... Will use echinocandin to refer to both echinocandins and pneumocandins ...
Lilly Pharmaceuticals. Merck Research Laboratories. Ortho-Biotech. Pfizer, Inc. ... Will use echinocandin to refer to both echinocandins and pneumocandins ...
| PowerPoint PPT presentation | free to view
LIPIDBASED ANTIFUNGAL AGENTS PowerPoint PPT Presentation
LIPIDBASED ANTIFUNGAL AGENTS - Available for IV use as amphotericin B deoxycholate (Fungizone ... compartment. Endocytosis. Liposome. Lysosome. Fusion. Liposome. degradation. Endocytic. vesicle ...
Available for IV use as amphotericin B deoxycholate (Fungizone ... compartment. Endocytosis. Liposome. Lysosome. Fusion. Liposome. degradation. Endocytic. vesicle ...
| PowerPoint PPT presentation | free to view
High Dose AmBisome Treatment: what do we know? PowerPoint PPT Presentation
High Dose AmBisome Treatment: what do we know? - 40 years clinical experience with drug. Efficacy shown against most yeast and ... Investigations and splenic aspirations were done on day 0, 21 and day 180 ...
40 years clinical experience with drug. Efficacy shown against most yeast and ... Investigations and splenic aspirations were done on day 0, 21 and day 180 ...
| PowerPoint PPT presentation | free to view
J Peter Donnelly PowerPoint PPT Presentation
J Peter Donnelly - J Peter Donnelly
J Peter Donnelly
| PowerPoint PPT presentation | free to view
Invasive aspergillosis PowerPoint PPT Presentation
Invasive aspergillosis - Invasive aspergillosis in patients taking steroids Alessandro C. Pasqualotto pasqualotto@santacasa.tche.br Santa Casa de Porto Alegre Many of these patients were also ...
Invasive aspergillosis in patients taking steroids Alessandro C. Pasqualotto pasqualotto@santacasa.tche.br Santa Casa de Porto Alegre Many of these patients were also ...
| PowerPoint PPT presentation | free to view
Carbapenem Resistance in Enterobacteriaceae PowerPoint PPT Presentation
Carbapenem Resistance in Enterobacteriaceae - Carbapenem Resistance in Enterobacteriaceae Jean B. Patel, PhD, (D)ABMM Leader, Antimicrobial Resistance Team Division of Healthcare Quality Promotion
Carbapenem Resistance in Enterobacteriaceae Jean B. Patel, PhD, (D)ABMM Leader, Antimicrobial Resistance Team Division of Healthcare Quality Promotion
| PowerPoint PPT presentation | free to view
Pr Faouzi SALIBA PowerPoint PPT Presentation
Pr Faouzi SALIBA - Aspergillosis in Transplant patients Pr Faouzi SALIBA faouzi.saliba@ pbr.aphp.fr Facult de M decine Paris Sud R animation - Centre H pato-Biliaire
Aspergillosis in Transplant patients Pr Faouzi SALIBA faouzi.saliba@ pbr.aphp.fr Facult de M decine Paris Sud R animation - Centre H pato-Biliaire
| PowerPoint PPT presentation | free to download
Antimicrobial Pharmacodynamics: Concepts for Rational Selection and Dosing of Antibiotics PowerPoint PPT Presentation
Antimicrobial Pharmacodynamics: Concepts for Rational Selection and Dosing of Antibiotics - Title: What the @*#! is Pharmacodynamics?? Author: John F. Mohr Last modified by: drnabil Created Date: 7/8/2003 2:16:26 PM Document presentation format
Title: What the @*#! is Pharmacodynamics?? Author: John F. Mohr Last modified by: drnabil Created Date: 7/8/2003 2:16:26 PM Document presentation format
| PowerPoint PPT presentation | free to view
Tres Difficile PowerPoint PPT Presentation
Tres Difficile - Tres Difficile Stephen M. Brecher PhD Director of Microbiology VA Boston Health Care System West Roxbury, Massachusetts
Tres Difficile Stephen M. Brecher PhD Director of Microbiology VA Boston Health Care System West Roxbury, Massachusetts
| PowerPoint PPT presentation | free to download
Antifungal Prophylaxis in Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy Nina PowerPoint PPT Presentation
Antifungal Prophylaxis in Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy Nina - Cahill, Chest 97. 29% (4/14) vs. 1.7% (1/57), p = .004. Husni, Clin Infect Dis 98 ... High-risk group Retransplantation Enteric drainage, dialysis, retroperitoneal ...
Cahill, Chest 97. 29% (4/14) vs. 1.7% (1/57), p = .004. Husni, Clin Infect Dis 98 ... High-risk group Retransplantation Enteric drainage, dialysis, retroperitoneal ...
| PowerPoint PPT presentation | free to view
PCR-where have we gone? PowerPoint PPT Presentation
PCR-where have we gone? - Early diagnosis of the infection may be improved if ... Mort. 30 days. IFI in treated. AF therapy. IFI proven/ probable. 15 candidiasis, 8 aspergillosis, ...
Early diagnosis of the infection may be improved if ... Mort. 30 days. IFI in treated. AF therapy. IFI proven/ probable. 15 candidiasis, 8 aspergillosis, ...
| PowerPoint PPT presentation | free to view
Liposomal amphotericin B: 20 years of clinical experience PowerPoint PPT Presentation
Liposomal amphotericin B: 20 years of clinical experience - Assistant Professor of Medicine and Epidemiology ... Walsh: Breakthru IFI, AmB-D: 8%, LAMB: 3% Defined disease. Histo/AIDS/LAMB, n=73 (Johnson, 2000) ...
Assistant Professor of Medicine and Epidemiology ... Walsh: Breakthru IFI, AmB-D: 8%, LAMB: 3% Defined disease. Histo/AIDS/LAMB, n=73 (Johnson, 2000) ...
| PowerPoint PPT presentation | free to view
Sin ttulo de diapositiva PowerPoint PPT Presentation
Sin ttulo de diapositiva - Innate immune system is the 'third column' of the immun system ... Herpes Zoster. Recurrent Herpes simplex. Progressive multifocal leukencephalopathy ...
Innate immune system is the 'third column' of the immun system ... Herpes Zoster. Recurrent Herpes simplex. Progressive multifocal leukencephalopathy ...
| PowerPoint PPT presentation | free to view
Catching-up with the Red Queen: Vancomycin MIC and clinical outcomes in severe MRSA infections PowerPoint PPT Presentation
Catching-up with the Red Queen: Vancomycin MIC and clinical outcomes in severe MRSA infections - 'Through the Looking-Glass', by Lewis Carroll. The Red Queen ' ... Now, here, you see, it takes all the running you can do, to keep in the same place...
'Through the Looking-Glass', by Lewis Carroll. The Red Queen ' ... Now, here, you see, it takes all the running you can do, to keep in the same place...
| PowerPoint PPT presentation | free to view
The Role of Environmental Surfaces in Healthcare Infections Philip C. Carling, M.D. Boston Universit PowerPoint PPT Presentation
The Role of Environmental Surfaces in Healthcare Infections Philip C. Carling, M.D. Boston Universit - The Role of Environmental Surfaces in Healthcare Infections. Philip C. Carling, M.D. ... Current Issues with Isolation. Extremely Difficult to Implement and Maintain ...
The Role of Environmental Surfaces in Healthcare Infections. Philip C. Carling, M.D. ... Current Issues with Isolation. Extremely Difficult to Implement and Maintain ...
| PowerPoint PPT presentation | free to view
Statin Interactions with NNRTIs and PIs PowerPoint PPT Presentation
Statin Interactions with NNRTIs and PIs - Statin Interactions with NNRTIs and PIs. Joanne J. Orrick, PharmD, AAHIVE ... Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 5.2. ...
Statin Interactions with NNRTIs and PIs. Joanne J. Orrick, PharmD, AAHIVE ... Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 5.2. ...
| PowerPoint PPT presentation | free to view
THE MIRACULOUS RETURN OF' PowerPoint PPT Presentation
THE MIRACULOUS RETURN OF' - Adapted from RH Rubin, Boston. TRANSPLANTATION A HYPE? ... Burns. HIV. TIMING OF FUNGAL INFECTIONS AFTER SOLID ORGAN TRANSPLANT. Snydman Clin Infect Dis. ...
Adapted from RH Rubin, Boston. TRANSPLANTATION A HYPE? ... Burns. HIV. TIMING OF FUNGAL INFECTIONS AFTER SOLID ORGAN TRANSPLANT. Snydman Clin Infect Dis. ...
| PowerPoint PPT presentation | free to view
WHY, WHEN AND HOW? PowerPoint PPT Presentation
WHY, WHEN AND HOW? - Title: EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER Author: PowerMac 7200, BdP Last modified by: jjj Created Date: 2/22/1999 10:04:01 PM
Title: EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER Author: PowerMac 7200, BdP Last modified by: jjj Created Date: 2/22/1999 10:04:01 PM
| PowerPoint PPT presentation | free to view
Infections in Cancer Patients Antifungal Drugs PowerPoint PPT Presentation
Infections in Cancer Patients Antifungal Drugs - Infections in Cancer Patients Antifungal Drugs
Infections in Cancer Patients Antifungal Drugs
| PowerPoint PPT presentation | free to view
Carbapenem Resistance in Enterobacteriaceae PowerPoint PPT Presentation
Carbapenem Resistance in Enterobacteriaceae - Susceptibility Profile of KPC-Producing K. pneumoniae. Tigecycline ... Variable susceptibility to cefoxitin and cefepime. Reading Disk Diffusion & Etest ...
Susceptibility Profile of KPC-Producing K. pneumoniae. Tigecycline ... Variable susceptibility to cefoxitin and cefepime. Reading Disk Diffusion & Etest ...
| PowerPoint PPT presentation | free to view
Cost-effectiveness of HIV Care: From RNA to HAART to Medicaid PowerPoint PPT Presentation
Cost-effectiveness of HIV Care: From RNA to HAART to Medicaid - Am liorer le d pistage pour traiter plus t t. Eric Billaud Infectiologie CHU Nantes Corevih des Pays de la Loire contact@corevih-pdl.fr Pl ni re COREVIH ...
Am liorer le d pistage pour traiter plus t t. Eric Billaud Infectiologie CHU Nantes Corevih des Pays de la Loire contact@corevih-pdl.fr Pl ni re COREVIH ...
| PowerPoint PPT presentation | free to download
ANTIVIRALS and IMMUNOTHERAPIES in PANDEMIC INFLUENZA NVAC Pandemic Influenza Working Group Briefing PowerPoint PPT Presentation
ANTIVIRALS and IMMUNOTHERAPIES in PANDEMIC INFLUENZA NVAC Pandemic Influenza Working Group Briefing - Yes. Common. Mild. GI. Oseltamivir. No. Very un-common. Mild- severe. Broncho-spasm. Zanamivir ... Yes. Yes. 10-30% Common. Mild- severe. Mild. CNS. GI ...
Yes. Common. Mild. GI. Oseltamivir. No. Very un-common. Mild- severe. Broncho-spasm. Zanamivir ... Yes. Yes. 10-30% Common. Mild- severe. Mild. CNS. GI ...
| PowerPoint PPT presentation | free to view
Latest Developments in the Treatment of Invasive Aspergillosis PowerPoint PPT Presentation
Latest Developments in the Treatment of Invasive Aspergillosis - Assistant Professor of Pediatrics, Molecular Genetics, and Microbiology. Pediatric Infectious Diseases. Duke University Medical Center. Durham, NC USA ...
Assistant Professor of Pediatrics, Molecular Genetics, and Microbiology. Pediatric Infectious Diseases. Duke University Medical Center. Durham, NC USA ...
| PowerPoint PPT presentation | free to view
Antimicrobial Resistance in Canada PowerPoint PPT Presentation
Antimicrobial Resistance in Canada - Is the leading cause of infectious morbidity and ... Each year in Canada it accounts for 5,000 cases of bloodstream ... Canadian Nosocomial Infection ...
Is the leading cause of infectious morbidity and ... Each year in Canada it accounts for 5,000 cases of bloodstream ... Canadian Nosocomial Infection ...
| PowerPoint PPT presentation | free to view
Paolo Grossi PowerPoint PPT Presentation
Paolo Grossi - Le infezioni nelle Unit di Terapia Intensiva: possibile ridurne l incidenza? Paolo Grossi Clinica Malattie Infettive e Tropicali Universit degli Studi dell ...
Le infezioni nelle Unit di Terapia Intensiva: possibile ridurne l incidenza? Paolo Grossi Clinica Malattie Infettive e Tropicali Universit degli Studi dell ...
| PowerPoint PPT presentation | free to download
Controlling Nosocomial MRSA and VRE Infections By Using Active Surveillance Cultures and Contact Pre PowerPoint PPT Presentation
Controlling Nosocomial MRSA and VRE Infections By Using Active Surveillance Cultures and Contact Pre - Controlling Nosocomial MRSA and VRE Infections By Using Active Surveillance Cultures and Contact Pre
Controlling Nosocomial MRSA and VRE Infections By Using Active Surveillance Cultures and Contact Pre
| PowerPoint PPT presentation | free to view
Overcoming Treatment Challenges in the TreatmentExperienced Patient With HIV A Review of New Antiret PowerPoint PPT Presentation
Overcoming Treatment Challenges in the TreatmentExperienced Patient With HIV A Review of New Antiret - Overcoming Treatment Challenges in the Treatment-Experienced Patient With HIV A ... 1. Fundaci n Huesped, Buenos Aires, Argentina; 2. Duke University, Durham, NC, USA ...
Overcoming Treatment Challenges in the Treatment-Experienced Patient With HIV A ... 1. Fundaci n Huesped, Buenos Aires, Argentina; 2. Duke University, Durham, NC, USA ...
| PowerPoint PPT presentation | free to download
New Drug Update: Whats in the pipeline PowerPoint PPT Presentation
New Drug Update: Whats in the pipeline - Between '87 and '95, 4 antiretrovials were launched. Since '95, 24 new products have been introduced. 25 years of ... Common ADR: diarrhea, rash, ISR, pyrexia ...
Between '87 and '95, 4 antiretrovials were launched. Since '95, 24 new products have been introduced. 25 years of ... Common ADR: diarrhea, rash, ISR, pyrexia ...
| PowerPoint PPT presentation | free to view
TDM of HIV PowerPoint PPT Presentation
TDM of HIV - INDINAVIR DOSE, CONCENTRATION, AND NEPHROTOXICITY ... IDV Cmin was not associated with nephrotoxicity ... increase the risk of nephrotoxicity in some regimens ...
INDINAVIR DOSE, CONCENTRATION, AND NEPHROTOXICITY ... IDV Cmin was not associated with nephrotoxicity ... increase the risk of nephrotoxicity in some regimens ...
| PowerPoint PPT presentation | free to view
Diapositiva%201 PowerPoint PPT Presentation
Diapositiva%201 - Modelos matem ticos que describen la relaci n entre la ... Efecto Post-Antibi tico In Vitro. Staphylococci Streptococci Coliforms Pseudomonas. Penicillins ...
Modelos matem ticos que describen la relaci n entre la ... Efecto Post-Antibi tico In Vitro. Staphylococci Streptococci Coliforms Pseudomonas. Penicillins ...
| PowerPoint PPT presentation | free to download
BMS Data Update PowerPoint PPT Presentation
BMS Data Update - BMS Data Update Dr Keith Aizen and Victoria Adamson Bristol-Myers Squibb Prescribing and adverse event reporting information can be found at the end of this presentation
BMS Data Update Dr Keith Aizen and Victoria Adamson Bristol-Myers Squibb Prescribing and adverse event reporting information can be found at the end of this presentation
| PowerPoint PPT presentation | free to download
Microscopic Observation and Culture of Aspergillus species: The Traditional Way PowerPoint PPT Presentation
Microscopic Observation and Culture of Aspergillus species: The Traditional Way - Who is a Clinical Laboratory Scientist (CLS) ... Septum. cmazzanti, CMVL,Stanford. 6. Microscopy in the Clinical Lab: The Critical Tools ...
Who is a Clinical Laboratory Scientist (CLS) ... Septum. cmazzanti, CMVL,Stanford. 6. Microscopy in the Clinical Lab: The Critical Tools ...
| PowerPoint PPT presentation | free to view
WHY, WHEN AND HOW? PowerPoint PPT Presentation
WHY, WHEN AND HOW? - diabetes renal insufficiency cvc hyperalimentation ... Within 1 week after onset of symptoms. More than 1 week. 74% 51% TIMING OF THE INTERVENTION ...
diabetes renal insufficiency cvc hyperalimentation ... Within 1 week after onset of symptoms. More than 1 week. 74% 51% TIMING OF THE INTERVENTION ...
| PowerPoint PPT presentation | free to view
Medication Adherence: What Can We Do to Help Patients Stick to Therapy PowerPoint PPT Presentation
Medication Adherence: What Can We Do to Help Patients Stick to Therapy - OR 1.16 (1.06-1.26) / 10% adh 1. Lower CD4 count increase 6 versus 83 cell/ml increase 2 ... Caring for others: Putting off care 2. Women OR 1.6 (1.2 - 2.2) ...
OR 1.16 (1.06-1.26) / 10% adh 1. Lower CD4 count increase 6 versus 83 cell/ml increase 2 ... Caring for others: Putting off care 2. Women OR 1.6 (1.2 - 2.2) ...
| PowerPoint PPT presentation | free to view
Antimicrobial consumption and impact on resistance PowerPoint PPT Presentation
Antimicrobial consumption and impact on resistance - Title: Presentaci n de PowerPoint Author: umic9 Last modified by: akmdmin Created Date: 1/7/2004 9:25:30 AM Document presentation format: Bildschirmpr sentation
Title: Presentaci n de PowerPoint Author: umic9 Last modified by: akmdmin Created Date: 1/7/2004 9:25:30 AM Document presentation format: Bildschirmpr sentation
| PowerPoint PPT presentation | free to view


Home About Us Terms and Conditions Privacy Policy Contact Us
Copyright 2024 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
icaac — Search results on PowerShow.com